Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance

Diaz, Annerleim Walton; Shakir, Nabeel; George, Arvin; Rais‐Bahrami, Soroush; Türkbey, Barış; Rothwax, Jason; Stamatakis, Lambros; Hong, Cheng William; Siddiqui, Mohummad Minhaj; Okoro, Chinonyerem; Raskolnikov, Dima; Su, Daniel; Shih, Joanna H.; Han, Hui; Parnes, Howard L.; Merino, María J.; Simon, Richard; Wood, Bradford J.; Choyke, Peter L.; Pinto, Peter A.

doi:10.1016/j.urolonc.2015.01.023

Cited by 135 publications

(68 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Imaging techniques such as MRI represent an example [19][20][21]. Despite the promising role of such modalities, strict formal testing of their ability to predict upstaging has not been reported.…”

Section: Discussionmentioning

confidence: 99%

A proposal of a new nomogram for predicting upstaging in contemporary D’Amico low-risk prostate cancer patients

et al. 2016

View full text Add to dashboard Cite

Our proposed nomogram is capable to accurately identify D'Amico low-risk patients at risk of upstaging, utilizing four routinely available clinical variables, age, PSA, prostate volume and percentage of positive biopsy cores. Unfavorable prostate cancer disease at final pathology affects at least 10 % of D'Amico low-risk patients. Thus, we developed and externally validated a new nomogram based on contemporary low-risk prostate cancer patients to accurately identify D'Amico low-risk patients at risk of upstaging. It utilizes four routine variables, age, PSA, prostate volume and percentage of positive biopsy cores.

show abstract

Section: Discussionmentioning

confidence: 99%

A proposal of a new nomogram for predicting upstaging in contemporary D’Amico low-risk prostate cancer patients

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Although experience in this area is limited, converging evidence from MRI-based AS cohorts suggests that serial imaging improves the prediction of pathological progression compared to clinicopathological variables alone, whereas stable MRI findings are associated with pathological stability [46,47,48]. A meta-analysis of MRI performance involving a total of 1028 surveillance patients demonstrated a low positive predictive value and sensitivity but a high negative predictive value and specificity, suggesting that although a negative MRI is reassuring, men with suspicious MRI lesions should be closely monitored [49].…”

Section: Mri In Active Surveillancementioning

confidence: 99%

When no treatment is the best treatment: Active surveillance strategies for low risk prostate cancers

Stavrinides

Parker

Moore

2017

Cancer Treatment Reviews

View full text Add to dashboard Cite

Title:When no treatment is the best treatment: active surveillance strategies for low risk prostate cancers. Abstract:Although the incidence of prostate cancer is rising due to PSA screening and increased life expectancy, the metastatic potential of low-grade, organ-confined disease remainslow. An increasing number of studies suggest that radical treatment in such cases confers little or no survival benefit at a significant cost to morbidity. Active surveillance is a promising management approach of such low-risk cancers: eligible patients are selected based on clinical and pathological findings at diagnosis and are regularly monitored with digital rectal examinations, PSA testing and biopsies. Treatment, however, is deferred until and unless there is evidence of disease progression. This is a key difference from watchful waiting, where treatment is avoided until and unless there are symptoms. The purpose of this work is to review the rationale and evidence behind active surveillance and to offer an overview of current active surveillance strategies and outcomes.

show abstract

“…The number needed to biopsy for one Gleason progression was 8.74 for standard 12-core repeat biopsy and 2.90 for fusion biopsy. Stable mpMRI findings were associated with Gleason score stability (28). These studies support the use of serial imaging and fusion biopsy in AS patients.…”

Section: Indications For Fusion Biopsymentioning

confidence: 99%

Magnetic Resonance Imaging-Ultrasound Fusion-Guided Prostate Biopsy: Review of Technology, Techniques, and Outcomes

et al. 2016

Self Cite

View full text Add to dashboard Cite

Transrectal ultrasound (TRUS)-guided (12–14 core) systematic biopsy of the prostate is the recommended standard for patients with suspicion of prostate cancer (PCa). Advances in imaging have led to the application of magnetic resonance imaging (MRI) for the detection of PCa with subsequent development of software-based co-registration allowing for the integration of MRI with real-time TRUS during prostate biopsy. A number of fusion-guided methods and platforms are now commercially available with common elements in image and analysis and planning. Implementation of fusion-guided prostate biopsy has now been proven to improve the detection of clinically significant PCa in appropriately selected patients.

show abstract

Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance

Cited by 135 publications

References 29 publications

A proposal of a new nomogram for predicting upstaging in contemporary D’Amico low-risk prostate cancer patients

A proposal of a new nomogram for predicting upstaging in contemporary D’Amico low-risk prostate cancer patients

When no treatment is the best treatment: Active surveillance strategies for low risk prostate cancers

Magnetic Resonance Imaging-Ultrasound Fusion-Guided Prostate Biopsy: Review of Technology, Techniques, and Outcomes

Contact Info

Product

Resources

About